GlassScriptPhysician profile
David Trevarthen
NPI 1225057631
$5,241.91
in general payments reported to CMS, 2019-2025
62 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,254 · 2020: $1,068 · 2021: $588 · 2022: $188 · 2023: $261 · 2024: $499 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.14 |
| Education | $149.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $371.23 | 2019-2025 | |
| Genentech USA, INC. | $341.06 | 2019-2024 | Perjeta, Venclexta, Phesgo |
| Merck Sharp & Dohme LLC | $269.80 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $268.42 | 2019-2021 | |
| Astellas Pharma US INC | $247.50 | 2019-2024 | |
| Genzyme Corporation | $242.70 | 2019-2023 | |
| Janssen Biotech, INC. | $239.70 | 2019-2025 | Talvey, Darzalex, Carvykti |
| Amgen INC. | $227.36 | 2019-2022 | |
| Pfizer INC. | $212.70 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $208.81 | 2019-2025 | Lynparza |
| Octapharma USA, INC. | $173.46 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $165.53 | 2019-2024 | Alunbrig, Ninlaro |
| Lilly USA, LLC | $114.21 | 2019-2021 | |
| Celgene Corporation | $105.88 | 2019-2022 | |
| Taiho Oncology, INC. | $101.28 | 2019-2025 |
Show all 61 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Trevarthen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.